Edwards Lifesciences (EW) slips 3.3% as investors digest recent conference remarks and insider-selling filings

Edwards Lifesciences (EW) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to post-conference positioning and fresh attention on insider-selling disclosures, with investors also still weighing the company’s 2026 growth cadence after recent guidance reaffirmations. With no single blockbuster headline, the drop looks like a sentiment reset rather than a fundamental one-day change.

Details:

The company recently presented at major healthcare conferences, which can prompt near-term re-rating as investors parse commentary on procedure growth, product pipeline timing, and competitive dynamics.

A recent Form 4 showed the CFO exercised options and sold shares in March 2026 under a pre-established Rule 10b5-1 plan, which can weigh on near-term sentiment even when pre-scheduled.

In its latest quarterly update, Edwards reiterated its 2026 framework (including an 8% to 10% sales growth view and adjusted EPS guidance), leaving limited room for upside surprise if investors expected a raise.

Separately, the earlier court outcome that ended the proposed JenaValve acquisition remains an overhang for some investors focused on longer-term aortic regurgitation strategy.

Sources:

Edwards Lifesciences (Investor Relations/Press Release), U.S. Securities and Exchange Commission, Federal Trade Commission

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EW Insider Trading Activity

$EW insiders have traded $EW stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 7 sales selling 69,406 shares for an estimated $5,862,264.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 4 sales selling 47,780 shares for an estimated $3,873,114.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 5 sales selling 33,700 shares for an estimated $2,834,401.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 4 sales selling 4,077 shares for an estimated $344,157.
HEISZ LESLIE STONE sold 2,615 shares for an estimated $218,119
DAVEEN CHOPRA (CVP, TMTT & Surgical) sold 2,000 shares for an estimated $168,750
WAYNE MARKOWITZ (CVP, JAPAC) sold 583 shares for an estimated $50,143

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$EW Hedge Fund Activity

We have seen 550 institutional investors add shares of $EW stock to their portfolio, and 666 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 16,954,947 shares (-75.9%) from their portfolio in Q4 2025, for an estimated $1,445,409,231
MILLENNIUM MANAGEMENT LLC added 4,301,241 shares (+241.7%) to their portfolio in Q4 2025, for an estimated $366,680,795
VIKING GLOBAL INVESTORS LP removed 3,069,151 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $261,645,122
HOLOCENE ADVISORS, LP removed 2,495,651 shares (-52.6%) from their portfolio in Q4 2025, for an estimated $212,754,247
MARSHALL WACE, LLP added 2,359,128 shares (+66.1%) to their portfolio in Q4 2025, for an estimated $201,115,662
CITADEL ADVISORS LLC removed 2,030,643 shares (-48.0%) from their portfolio in Q4 2025, for an estimated $173,112,315
FMR LLC added 2,003,735 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $170,818,408

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$EW Government Contracts

We have seen $28,146,162 of award payments to $EW over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

EXPRESS REPORT: HEART VALVES: $295,500
EXPRESS REPORT: 2ND QTR FY25 TAVR HEART VALVES WITH CONSIGNMENT DELIVERY: $261,500
HTM EV1000 PATIENT MONITORS: $246,000
HEART VALVE: $238,000
TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS: $238,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$EW Congressional Stock Trading

Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 11/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$EW Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/11/2026
Stifel issued a "Buy" rating on 01/20/2026
Piper Sandler issued a "Overweight" rating on 01/20/2026
Barclays issued a "Overweight" rating on 01/12/2026
TD Cowen issued a "Buy" rating on 01/09/2026
Mizuho issued a "Outperform" rating on 10/31/2025
RBC Capital issued a "Outperform" rating on 10/31/2025

To track analyst ratings and price targets for $EW, check out Quiver Quantitative's $EW forecast page.

$EW Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 17 analysts offer price targets for $EW in the last 6 months, with a median target of $100.0.

Here are some recent targets:

Adam Maeder from Piper Sandler set a target price of $100.0 on 02/11/2026
David Roman from Goldman Sachs set a target price of $95.0 on 02/11/2026
Marie Thibault from BTIG set a target price of $103.0 on 02/11/2026
Richard Newitter from Truist Securities set a target price of $89.0 on 02/11/2026
Larry Biegelsen from Wells Fargo set a target price of $100.0 on 02/11/2026
Rick Wise from Stifel set a target price of $110.0 on 01/20/2026
Matt Miksic from Barclays set a target price of $104.0 on 01/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.